Q1 2025

Filed May 8, 2025 · 10-Q · 38 days after period end · 0001802768-25-000027

Q1 2025 · 10-Q

Revenue

$568.25M

+0.0% vs Q1 2024

Net Income

$239.35M

+4,909.4% vs Q1 2024

EPS Diluted

$0.55

+5,400.0% vs Q1 2024

Operating Income$534,182,000N/M

Operating Cash Flow

Same quarter

Metric	Q1 2025	Q1 2024	Q1 2023	Q1 2022
Revenue	$568.25M	$567.98M	$683.97M	$562.05M
Net Income	$239.35M	$4.78M	$340.76M	$51.76M
EPS Diluted	$0.55	$0.01	$0.76	$0.12

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Royalty Pharma plc · CIK 1802768 · Engraved from SEC EDGAR